{"cluster": 36, "subcluster": 14, "abstract_summ": " Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by infections . CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly . Tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor, may ameliorate the CRS associated with severe CRS ."}